Diccianni MB - Search Results

1

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: diccianni mb. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.

2

Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia.

Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Diccianni MB, et al. Blood. 1994 Nov 1;84(9):3105-12. Blood. 1994. PMID: 7949183 Free article.

3

The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.

Diccianni MB, Chau LS, Batova A, Vu TQ, Yu AL. Diccianni MB, et al. Cancer Lett. 1996 Jul 12;104(2):183-92. doi: 10.1016/0304-3835(96)04250-4. Cancer Lett. 1996. PMID: 8665486

4

Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.

Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, Yu AL. Batova A, et al. Among authors: diccianni mb. Blood. 1996 Oct 15;88(8):3083-90. Blood. 1996. PMID: 8874207 Free article.

5

Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.

Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL. Batova A, et al. Among authors: diccianni mb. Cancer Res. 1997 Mar 1;57(5):832-6. Cancer Res. 1997. PMID: 9041181

6

Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions.

Diccianni MB, Batova A, Yu J, Vu T, Pullen J, Amylon M, Pollock BH, Yu AL. Diccianni MB, et al. Leuk Res. 1997 Jun;21(6):549-58. doi: 10.1016/s0145-2126(97)00007-6. Leuk Res. 1997. PMID: 9279366

7

Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.

Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. Diccianni MB, et al. Int J Cancer. 1999 Jan 5;80(1):145-54. doi: 10.1002/(sici)1097-0215(19990105)80:1<145::aid-ijc26>3.0.co;2-g. Int J Cancer. 1999. PMID: 9935245

8

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.

Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera CJ, Bridgeman LJ, Kung FH, Pullen J, Amylon MD, Yu AL. Batova A, et al. Among authors: diccianni mb. Cancer Res. 1999 Apr 1;59(7):1492-7. Cancer Res. 1999. PMID: 10197619

9

Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.

Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu AL. Omura-Minamisawa M, et al. Among authors: diccianni mb. Clin Cancer Res. 2000 Apr;6(4):1219-28. Clin Cancer Res. 2000. PMID: 10778944

10

Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia.

von Lintig FC, Huvar I, Law P, Diccianni MB, Yu AL, Boss GR. von Lintig FC, et al. Among authors: diccianni mb. Clin Cancer Res. 2000 May;6(5):1804-10. Clin Cancer Res. 2000. PMID: 10815901

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters